Mold-Tek Packaging Ltd

- The company expects capex to reduce considerably next year as most greenfield projects are completed. - Planned capex for next financial year is around INR 80 to 85 crores, primarily for Pharma segment expansion. - There is no explicit mention of new fundraising through debt or equity in the provided transcript. - The company is focusing on utilizing existing machinery and capacity efficiently, with planned expansions adding 10%-12% capacity. - Debt reduction is a focus, as discussed in dividend vs. debt repayment trade-off, suggesting prudent financial management rather than raising new funds. Hence, no clear current or future fundraising through debt or equity is indicated in the discussed period.

- Current year capex (FY 2025-26) is around INR 120 crores, down from INR 140 crores last year. - Next year (FY 2026-27) target capex is significantly lower at INR 80-85 crores, as most greenfield projects are completed except some work at Mahad. - Major expansion planned in Pharma segment next year, with estimated capex of INR 25 crores to develop new products like eye droppers and nasal droppers, with pilot molds already in development. - Future Pharma growth expected at 30% volume growth post reaching INR 50-55 crores revenue. - Addition of 21 more injection molding machines planned in next 3-6 months, enhancing capacity by 10-12%, targeting peak revenues of INR 1,150-1,200 crores. - Strategic MoU with Vibe Generation for high-value caps and closures in chemicals and lubricants, with commercial volumes expected from Q2 FY 2026-27 onwards.

- Target to cross INR 1,000 crores in top line next year, implying 13%-14% volume growth. (Page 6) - Aim for 12%-15% volume growth supported by segments showing healthy double-digit growth. (Page 6) - Food and FMCG segment expected to achieve mid-teen growth with a pick-up from Q4 and summer season. (Page 13) - Q-Pack segment to continue growing around 25%-30%. (Page 13) - Pharma segment target of INR 50-55 crores next year, with 30%-35% volume growth anticipated. (Page 6, 13) - Paint segment expected to grow double-digits driven by Asian Paints and Berger growth. (Page 6, 13) - Lube segment expected to recover volumes next year after BPCL tender loss, with gains from new client Veedol. (Page 14) - Capacity expansion adding 10%-12% more capacity, enabling revenue potential of INR 1,150-1,200 crores. (Page 15) - Overall, 20%+ PAT growth expected next year aligned with EBITDA growth. (Page 6)

- PAT and EBITDA growth are expected to continue around 20% annually for the current and next financial year. - EBITDA growth projected at 20%-22% for the current year and around 12%-15% volume growth next year, targeting INR200-210 crores EBITDA. - PAT anticipated to grow slightly faster than EBITDA, possibly around 25% once depreciation tapers down after 1-2 years. - EPS has increased from 13.3 to 15.75 in the first nine months, with a healthy growth outlook. - Pharma segment aims for 40%-45% volume growth next year, significantly contributing to bottom-line growth. - Volume growth targets: 12%-15% overall, aiming to cross INR1,000 crores revenue next year. - Capex to reduce next year to INR80-85 crores, focusing on Pharma expansion. - Lubricants segment expected to remain stagnant with 2%-3% growth, while Food, FMCG, and Paints show healthy double-digit volume growth.

- The document does not explicitly state the current or expected orderbook or pending orders in exact numeric terms. - However, it mentions a "strong order book" in Pharma as of mid-January, indicating positive demand and expected growth. - The company's Q4 outlook seems optimistic, with strong momentum and expectations of matching Q1 volume levels. - New MOUs with clients such as Swiggy and Vibe Generation suggest potential for incremental future orders. - The management notes increased client confidence due to improved printing capacity and timely deliveries. - No specific consolidated order backlog numbers are disclosed in the provided transcript.